Ubs Oncology Impact Fund L.P. Oncorus, Inc. (ONCR) insider trading activity

Ubs Oncology Impact Fund L.P. is > 10% Shareholder of Oncorus, Inc.. Currently has a direct ownership of 2.38 Million shares of ONCR, which is worth approximately $0. The most recent transaction as insider was on Oct 06, 2020, when has been sold 151,224 shares (Common Stock) at a price of $15.0 per share, resulting in proceeds of $2,268,360. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 2.38M

0% 3M change

0% 12M change

Total Value Held $0

UBS Oncology Impact Fund L.P. Transaction History

Date	Transaction	Value	Shares Traded	Shares Held	Form
Oct 06 2020	BUY Open market or private purchase	$2,268,360 $15.0 p/Share	151,224 Added 5.98%	2,377,025 Common Stock
Oct 06 2020	BUY Conversion of derivative security	-	2,225,801 Added 50.0%	2,225,801 Common Stock

Also insider at

CGEM

Cullinan Oncology, Inc. Healthcare

> 10% Shareholder

TCRR

TCR2 THERAPEUTICS INC. Healthcare

> 10% Shareholder

HARP

Harpoon Therapeutics, Inc. Healthcare

> 10% Shareholder

UOI